Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Average Rating of “Buy” by Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received an average rating of “Buy” from the eleven brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $22.29.

Several analysts have recently commented on AUPH shares. Oppenheimer raised their target price on shares of Aurinia Pharmaceuticals from $14.00 to $22.00 in a research note on Thursday, December 5th. ValuEngine cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 5th. Bloom Burton restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 2nd. BidaskClub cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Cantor Fitzgerald raised their target price on shares of Aurinia Pharmaceuticals from $24.00 to $30.00 in a research note on Thursday, December 5th.

Several hedge funds have recently added to or reduced their stakes in the company. Stifel Financial Corp lifted its stake in shares of Aurinia Pharmaceuticals by 4.6% in the 3rd quarter. Stifel Financial Corp now owns 43,011 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,902 shares during the period. Toronto Dominion Bank lifted its stake in shares of Aurinia Pharmaceuticals by 26.3% in the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,575 shares during the period. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 42.9% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 3,000 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Aurinia Pharmaceuticals by 29.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,150 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 4,300 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 18.6% in the second quarter. Vanguard Group Inc. now owns 29,020 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,549 shares during the period. Institutional investors own 28.23% of the company’s stock.

NASDAQ:AUPH traded up $0.12 during trading hours on Tuesday, reaching $19.91. 2,156,618 shares of the company’s stock were exchanged, compared to its average volume of 2,192,652. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -26.20 and a beta of 1.68. The company has a 50-day moving average of $17.34 and a 200 day moving average of $8.62. Aurinia Pharmaceuticals has a 1-year low of $3.52 and a 1-year high of $21.93.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.05 million. Equities research analysts forecast that Aurinia Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: What does an equal weight rating mean?

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.